Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Angiogenix Raises $12M In Series C For Acclaim Product

Dec. 19, 2002

By Aaron Lorenzo

Targeted Genetics Continues Cutbacks To Conserve Cash

Dec. 18, 2002

By Aaron Lorenzo

Versicor Starts Phase III Trials Of Dalbavancin For Infections

Dec. 18, 2002

By Aaron Lorenzo

Targeted Genetics Continues Cutbacks To Conserve Cash

Dec. 18, 2002

By Aaron Lorenzo

Versicor Starts Phase III Trials Of Dalbavancin For Infections

Dec. 18, 2002

By Aaron Lorenzo

AdipoGenix Lands Deal With J&J For Program In Obesity

Dec. 17, 2002

By Aaron Lorenzo

AdipoGenix Lands Deal With J&J For Program In Obesity

Dec. 17, 2002

By Aaron Lorenzo

Neurochem Raises C$8M, Could Realize More With Warrants Sale

Dec. 13, 2002

By Aaron Lorenzo

Neurochem Raises C$8M, Could Realize More With Warrants Sale

Dec. 13, 2002

By Aaron Lorenzo

Northwest, Medarex, Millennium Dealing Cancer Products, IP

Dec. 12, 2002

By Aaron Lorenzo

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...